Senseonics (NYSE:SENS) Trading Up 7.8%

Shares of Senseonics Holdings, Inc. (NYSE:SENS) were up 7.8% during mid-day trading on Tuesday . The company traded as high as $0.43 and last traded at $0.43. Approximately 1,628,010 shares changed hands during trading, a decline of 35% from the average daily volume of 2,487,652 shares. The stock had previously closed at $0.40.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Senseonics to a “sell” rating in a report on Friday, March 29th.

Senseonics Stock Performance

The company has a market cap of $228.25 million, a PE ratio of -3.91 and a beta of 0.87. The company has a current ratio of 7.53, a quick ratio of 7.03 and a debt-to-equity ratio of 1.15. The business’s 50 day moving average is $0.57.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Senseonics had a negative net margin of 270.13% and a negative return on equity of 146.90%. The company had revenue of $8.00 million for the quarter, compared to analyst estimates of $7.62 million. On average, equities research analysts predict that Senseonics Holdings, Inc. will post -0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Cornerstone Wealth Management LLC grew its stake in Senseonics by 55.9% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 55,750 shares of the company’s stock valued at $34,000 after buying an additional 20,000 shares during the last quarter. Ausdal Financial Partners Inc. grew its stake in Senseonics by 53.2% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 72,000 shares of the company’s stock valued at $43,000 after buying an additional 25,000 shares during the last quarter. Finally, RPO LLC acquired a new position in Senseonics in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.